同源康医药-B(02410)

13.110-0.080-0.61%

社区社区
资讯资讯
资料资料
公告公告

- 最新
- 推荐
公司概况
公司名称
同源康医药-B
所属市场
SEHK
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
- -
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。该公司专注于小分子药物开发，其主要产品包括TY-9591、TY-302和TY-2136。TY-9591是一种第三代EGFR-TKI，对EGFR突变具有抗肿瘤作用。TY-302是一种为治疗乳腺癌及前列腺癌等晚期实体瘤而开发的强效、选择性口服CDK4/6抑制剂。TY-2136b为自主研发、口服ROS1/NTRK抑制剂，用于治疗实体瘤。
- 2025-09-19
  半年度报告
  2025中期报告
  2025中期报告
- 2025-08-31
  须予披露的交易
  须予披露交易 - 认购理财产品；投资及赎回基金权益；及更新全球发售闲置资金用途
  须予披露交易 - 认购理财产品；投资及赎回基金权益；及更新全球发售闲置资金用途
- 2025-08-31
  半年度报告
  截至2025年6月30日止六个月中期业绩公告；非执行董事辞任；及建议修订组织章程细则
  截至2025年6月30日止六个月中期业绩公告；非执行董事辞任；及建议修订组织章程细则
- 2025-08-04
  股份发行
  完成根据一般授权配售新H股
  完成根据一般授权配售新H股
- 2025-07-29
  股份发行
  根据一般授权配售新H股
  根据一般授权配售新H股
- 2025-04-29
  年度报告
  2024年度报告
  2024年度报告
- 2025-03-27
  年度报告
  截至2024年12月31日止年度年度业绩公告；非执行董事辞任；及建议修订组织章程细则
  截至2024年12月31日止年度年度业绩公告；非执行董事辞任；及建议修订组织章程细则
- 2024-09-27
  半年度报告
  2024中期报告
  2024中期报告
- 2024-08-30
  半年度报告
  截至2024年6月30日止六个月中期业绩公告
  截至2024年6月30日止六个月中期业绩公告
- 2024-08-12
  股份发售
  全球发售
  全球发售

分时
5日
日
周
月

数据加载中...

最高

13.550

今开

13.010

量比

1.70

最低

12.940

昨收

13.190

换手率

0.45%

热议股票

{"pagemeta":{"title":"同源康医药-B(02410)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供同源康医药-B(02410)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"同源康医药-B,02410,同源康医药-B股票,同源康医药-B股票老虎,同源康医药-B股票老虎国际,同源康医药-B行情,同源康医药-B股票行情,同源康医药-B股价,同源康医药-B股市,同源康医药-B股票价格,同源康医药-B股票交易,同源康医药-B股票购买,同源康医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"同源康医药-B(02410)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供同源康医药-B(02410)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"community","symbol":"02410","data":{"stockData":{"symbol":"02410","market":"HK","secType":"STK","nameCN":"同源康医药-B","latestPrice":13.11,"timestamp":1767154109006,"preClose":13.19,"halted":0,"volume":1691500,"delay":0,"floatShares":375457818,"shares":380065818,"eps":-1.2784173759087725,"marketStatus":"元旦节休市","change":-0.08,"latestTime":"12-31 12:08:29","open":13.01,"high":13.55,"low":12.94,"amount":22558185,"amplitude":0.046247,"askPrice":13.16,"askSize":13000,"bidPrice":13.11,"bidSize":3500,"shortable":3,"etf":0,"ttmEps":-0.8609565290028801,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767317400000},"marketStatusCode":7,"adr":0,"listingDate":1724083200000,"exchange":"SEHK","adjPreClose":13.19,"openAndCloseTimeList":[[1767144600000,1767153600000]],"volumeRatio":1.7036114605093748,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"tweetData":{"bottom":false,"list":[{"cardType":"TWEET","cardId":"TWEET.516596337321184","cardData":[{"tweetId":"516596337321184","author":{"authorId":"4184381897673700","idStr":"4184381897673700","name":"曼曼在海南","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 固体制剂工厂一期预计2026年完成GMP认证，年产能1.5亿片剂，支撑商业化生产","plainDigest":"$同源康医药-B(02410)$ 固体制剂工厂一期预计2026年完成GMP认证，年产能1.5亿片剂，支撑商业化生产","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1767151439869,"gmtModify":1767151441860,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":65,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/516596337321184","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":89,"displayRows":2,"foldSize":0,"authorId":"4184381897673700"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.516405869982496","cardData":[{"tweetId":"516405869982496","author":{"authorId":"3574483855983034","idStr":"3574483855983034","name":"行稳致远之","avatar":"https://static.laohu8.com/default-avatar.jpg","userType":1,"introduction":"","crmLevel":2,"crmLevelSwitch":0,"wearingBadge":{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0},"individualDisplayBadges":[],"fanSize":24,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$</a> 日k线来看，有希望走出大反弹的技术形态","plainDigest":"$同源康医药-B(02410)$ 日k线来看，有希望走出大反弹的技术形态","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1767104861556,"gmtModify":1767104865425,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":1,"images":[{"url":"https://static.tigerbbs.com/75a930e282d67053dc28822456879eef","width":"428","height":"336"}],"repostCount":0,"viewCount":168,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/516405869982496","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":57,"displayRows":2,"foldSize":0,"authorId":"3574483855983034"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.515995343196664","cardData":[{"tweetId":"515995343196664","author":{"authorId":"4184380269673420","idStr":"4184380269673420","name":"骏马飞驰吧","avatar":"https://static.tigerbbs.com/d3702f332c2e6980d8637b92198e2a1c","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":11,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> TY-00540在乳腺癌模型中展现广谱抗肿瘤潜力，TY-302联合疗法安全性获验证，国际认可度强","plainDigest":"$同源康医药-B(02410)$ TY-00540在乳腺癌模型中展现广谱抗肿瘤潜力，TY-302联合疗法安全性获验证，国际认可度强","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1766996190020,"gmtModify":1766996192364,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":95,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/515995343196664","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":101,"displayRows":2,"foldSize":0,"authorId":"4184380269673420"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.515896186765864","cardData":[{"tweetId":"515896186765864","author":{"authorId":"4108169277080930","idStr":"4108169277080930","name":"音浪太强","avatar":"https://static.laohu8.com/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 药物临床试验登记与信息公示平台数据显示，浙江同源康医药股份有限公司的一项评估TEAD抑制剂TYK-01054胶囊在局部进展或转移性晚期实体瘤患者中的安全性、耐受性、药代动力学和抗肿瘤活性的I/II期、开放标签、多中心研究已启动。临床试验登记号为CTR20255003，首次公示信息日期为2025年12月26日。","plainDigest":"$同源康医药-B(02410)$ 药物临床试验登记与信息公示平台数据显示，浙江同源康医药股份有限公司的一项评估TEAD抑制剂TYK-01054胶囊在局部进展或转移性晚期实体瘤患者中的安全性、耐受性、药代动力学和抗肿瘤活性的I/II期、开放标签、多中心研究已启动。临床试验登记号为CTR20255003，首次公示信息日期为2025年12月26日。","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1766981674809,"gmtModify":1766981677284,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":85,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/515896186765864","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":287,"displayRows":2,"foldSize":0,"authorId":"4108169277080930"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.514384110370824","cardData":[{"tweetId":"514384110370824","author":{"authorId":"4214049281636630","idStr":"4214049281636630","name":"永远的话事人","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 提前休市了，只能等下周一的再来看看有没有反弹","plainDigest":"$同源康医药-B(02410)$ 提前休市了，只能等下周一的再来看看有没有反弹","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1766556397714,"gmtModify":1766556399814,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":281,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/514384110370824","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":64,"displayRows":2,"foldSize":0,"authorId":"4214049281636630"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.513774148551688","cardData":[{"tweetId":"513774148551688","author":{"authorId":"4184380269673420","idStr":"4184380269673420","name":"骏马飞驰吧","avatar":"https://static.tigerbbs.com/d3702f332c2e6980d8637b92198e2a1c","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":11,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 固体制剂工厂一期预计2026年完成GMP认证，年产能1.5亿片剂，支撑商业化生产","plainDigest":"$同源康医药-B(02410)$ 固体制剂工厂一期预计2026年完成GMP认证，年产能1.5亿片剂，支撑商业化生产","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1766478756047,"gmtModify":1766478758003,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":289,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/513774148551688","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":89,"displayRows":2,"foldSize":0,"authorId":"4184380269673420"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.513522215989560","cardData":[{"tweetId":"513522215989560","author":{"authorId":"4204683525604390","idStr":"4204683525604390","name":"龙龙行天下","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 今天又是收阴线，不知道明天是不是轮到收阳线","plainDigest":"$同源康医药-B(02410)$ 今天又是收阴线，不知道明天是不是轮到收阳线","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1766417182655,"gmtModify":1766417184599,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":192,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/513522215989560","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":62,"displayRows":2,"foldSize":0,"authorId":"4204683525604390"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.512180009513272","cardData":[{"tweetId":"512180009513272","author":{"authorId":"4136460772891970","idStr":"4136460772891970","name":"牛熊两吃","avatar":"https://static.laohu8.com/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":12,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$</a> 同源康现在又企稳30日均线之上，短期趋势相对看好","plainDigest":"$同源康医药-B(02410)$ 同源康现在又企稳30日均线之上，短期趋势相对看好","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1766070908272,"gmtModify":1766070912524,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":1,"images":[{"url":"https://static.tigerbbs.com/a8e52a319e063bcf800be69e3be907d2","width":"428","height":"336"}],"repostCount":0,"viewCount":373,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/512180009513272","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":66,"displayRows":2,"foldSize":0,"authorId":"4136460772891970"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.511632220570088","cardData":[{"tweetId":"511632220570088","author":{"authorId":"4184381897673700","idStr":"4184381897673700","name":"曼曼在海南","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 核心在研产品TY-9591成功完成II期实验阶段，数据相当哇塞，后续产品有戏了","plainDigest":"$同源康医药-B(02410)$ 核心在研产品TY-9591成功完成II期实验阶段，数据相当哇塞，后续产品有戏了","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1765937173026,"gmtModify":1765937175260,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":373,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/511632220570088","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":88,"displayRows":2,"foldSize":0,"authorId":"4184381897673700"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.511470999553216","cardData":[{"tweetId":"511470999553216","author":{"authorId":"4218001298160580","idStr":"4218001298160580","name":"G股叶荣添","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 逆市上涨回来，今天这个收盘价确实是有点意外啊","plainDigest":"$同源康医药-B(02410)$ 逆市上涨回来，今天这个收盘价确实是有点意外啊","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1765897890834,"gmtModify":1765897892893,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":203,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/511470999553216","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":64,"displayRows":2,"foldSize":0,"authorId":"4218001298160580"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.511076523074368","cardData":[{"tweetId":"511076523074368","author":{"authorId":"4184380269673420","idStr":"4184380269673420","name":"骏马飞驰吧","avatar":"https://static.tigerbbs.com/d3702f332c2e6980d8637b92198e2a1c","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":11,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 同源康医药是一家专注于小分子药物开发的中国公司，核心产品包括TY-9591、TY-302和TY-2136","plainDigest":"$同源康医药-B(02410)$ 同源康医药是一家专注于小分子药物开发的中国公司，核心产品包括TY-9591、TY-302和TY-2136","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1765787412326,"gmtModify":1765787414285,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":461,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/511076523074368","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":103,"displayRows":2,"foldSize":0,"authorId":"4184380269673420"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.510068972986432","cardData":[{"tweetId":"510068972986432","author":{"authorId":"4108169277080930","idStr":"4108169277080930","name":"音浪太强","avatar":"https://static.laohu8.com/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 智通财经APP获悉，同源康医药-B(02410)早盘涨超5%，截至发稿， 涨3.73%，报13.35港元，成交额2154.6万港元","plainDigest":"$同源康医药-B(02410)$ 智通财经APP获悉，同源康医药-B(02410)早盘涨超5%，截至发稿， 涨3.73%，报13.35港元，成交额2154.6万港元","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1765514384593,"gmtModify":1765514386549,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":182,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/510068972986432","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":114,"displayRows":2,"foldSize":0,"authorId":"4108169277080930"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.509841360581064","cardData":[{"tweetId":"509841360581064","author":{"authorId":"3476670504434547","idStr":"3476670504434547","name":"木下上山虎","avatar":"https://static.laohu8.com/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":31,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ &nbsp;</a>今天还可以，又涨回来了，这是好现象","plainDigest":"$同源康医药-B(02410)$ 今天还可以，又涨回来了，这是好现象","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1765510931273,"gmtModify":1765510933075,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":557,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/509841360581064","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":53,"displayRows":2,"foldSize":0,"authorId":"3476670504434547"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.509552801595824","cardData":[{"tweetId":"509552801595824","author":{"authorId":"4218427800237090","idStr":"4218427800237090","name":"莎士比亚的微笑","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 已组建商业化团队，计划通过内外部合作构建营销网络，快速覆盖中国市场","plainDigest":"$同源康医药-B(02410)$ 已组建商业化团队，计划通过内外部合作构建营销网络，快速覆盖中国市场","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1765440481069,"gmtModify":1765440483410,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":277,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/509552801595824","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":85,"displayRows":2,"foldSize":0,"authorId":"4218427800237090"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.509273730085560","cardData":[{"tweetId":"509273730085560","author":{"authorId":"4204683525604390","idStr":"4204683525604390","name":"龙龙行天下","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 今天又回来了，又需要重新爬坡上升起来","plainDigest":"$同源康医药-B(02410)$ 今天又回来了，又需要重新爬坡上升起来","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1765372436655,"gmtModify":1765372438578,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":338,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/509273730085560","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":56,"displayRows":2,"foldSize":0,"authorId":"4204683525604390"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.508884222214368","cardData":[{"tweetId":"508884222214368","author":{"authorId":"4203843771083212","idStr":"4203843771083212","name":"乐山大佛笑哈哈","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 同源康医药的核心产品TY-9591是一款第三代EGFR-TKI抑制剂，通过氘代化学修饰显著提升血脑屏障穿透能力，同时减少有毒代谢物AZ5104的产生（降低60%），安全性优于奥希替尼","plainDigest":"$同源康医药-B(02410)$ 同源康医药的核心产品TY-9591是一款第三代EGFR-TKI抑制剂，通过氘代化学修饰显著提升血脑屏障穿透能力，同时减少有毒代谢物AZ5104的产生（降低60%），安全性优于奥希替尼","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1765270650203,"gmtModify":1765270652613,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":580,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/508884222214368","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":174,"displayRows":2,"foldSize":0,"authorId":"4203843771083212"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.508632690086616","cardData":[{"tweetId":"508632690086616","author":{"authorId":"4215766663851320","idStr":"4215766663851320","name":"爱打新的小燕子","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 整体还可以吧，算是稳住阵脚了，进入反弹阶段","plainDigest":"$同源康医药-B(02410)$ 整体还可以吧，算是稳住阵脚了，进入反弹阶段","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1765209322456,"gmtModify":1765209324184,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":221,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/508632690086616","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":61,"displayRows":2,"foldSize":0,"authorId":"4215766663851320"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.507627451429032","cardData":[{"tweetId":"507627451429032","author":{"authorId":"4193625296607780","idStr":"4193625296607780","name":"打铁不如李铁","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 同源康医药与默沙东合作里程碑的首付款，默沙东支付2亿美元首付款，获得TY-305（PD-1/CTLA-4双抗）大中华区以外独家开发权2","plainDigest":"$同源康医药-B(02410)$ 同源康医药与默沙东合作里程碑的首付款，默沙东支付2亿美元首付款，获得TY-305（PD-1/CTLA-4双抗）大中华区以外独家开发权2","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1764908510555,"gmtModify":1764908512442,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":849,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/507627451429032","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":132,"displayRows":2,"foldSize":0,"authorId":"4193625296607780"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.506628126577632","cardData":[{"tweetId":"506628126577632","author":{"authorId":"4184381897673700","idStr":"4184381897673700","name":"曼曼在海南","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 公司建立了包含11款候选药物的管线，覆盖肺癌、乳腺癌、前列腺癌等多种癌症适应症，涵盖临床阶段和临床前阶段项目，为未来发展提供了多元化的布局，逢低可大力介入","plainDigest":"$同源康医药-B(02410)$ 公司建立了包含11款候选药物的管线，覆盖肺癌、乳腺癌、前列腺癌等多种癌症适应症，涵盖临床阶段和临床前阶段项目，为未来发展提供了多元化的布局，逢低可大力介入","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1764719183939,"gmtModify":1764719186115,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":294,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/506628126577632","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":167,"displayRows":2,"foldSize":0,"authorId":"4184381897673700"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.506473059308632","cardData":[{"tweetId":"506473059308632","author":{"authorId":"3574483855983034","idStr":"3574483855983034","name":"行稳致远之","avatar":"https://static.laohu8.com/default-avatar.jpg","userType":1,"introduction":"","crmLevel":2,"crmLevelSwitch":0,"wearingBadge":{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0},"individualDisplayBadges":[],"fanSize":24,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$</a> 等着吧，12月还是很关键的节点，同源康应该还有机会升回来","plainDigest":"$同源康医药-B(02410)$ 等着吧，12月还是很关键的节点，同源康应该还有机会升回来","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1764681334691,"gmtModify":1764681336934,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":476,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/506473059308632","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":73,"displayRows":2,"foldSize":0,"authorId":"3574483855983034"}],"position":0}],"size":20,"extra":{"requestId":"ce5bd7b3403f40febb225ecfaafa6343","feedVerCode":"2"}},"newsData":null,"noticeData":{"listData":[{"cdn_pdf":true,"hasAttachments":false,"id":"20185733","market":"hk","labels":[],"media":"港交所","original_id":"N.HK529G9em8zu","pdf_url":"https://static.tigerbbs.com/baba20cef37d43d9a1b4365303cad8db","pub_time":1758270720000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2025中期报告","symbol":"02410","title":"2025中期报告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0919/2025091900443_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [中期/半年度报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2025-09-19 16:32","pubTimestamp":1758270720,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20112040","market":"hk","labels":[],"media":"港交所","original_id":"N.HKEBcbBF6ATz","pdf_url":"https://static.tigerbbs.com/375db4bf747e4d53a101c0ea7e90805f","pub_time":1756636620000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"须予披露交易 - 认购理财产品；投资及赎回基金权益；及更新全球发售闲置资金用途","symbol":"02410","title":"须予披露交易 - 认购理财产品；投资及赎回基金权益；及更新全球发售闲置资金用途","titleType":"须予披露的交易","type":"hkTrade","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0831/2025083100074_c.pdf","us_notice_code":"公告及通告 - [须予披露的交易 / 其他-杂项]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"交易相关","type_name_en":"Transaction Related","titleTypeEn":"","event_type":"important_notice","event_name":"须予披露的交易","pubTime":"2025-08-31 18:37","pubTimestamp":1756636620,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20112037","market":"hk","labels":[],"media":"港交所","original_id":"N.HK9qKjV1tTLN","pdf_url":"https://static.tigerbbs.com/23daaef8e7404155822c39fdfb71940a","pub_time":1756636200000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2025年6月30日止六个月中期业绩公告；非执行董事辞任；及建议修订组织章程细则","symbol":"02410","title":"截至2025年6月30日止六个月中期业绩公告；非执行董事辞任；及建议修订组织章程细则","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0831/2025083100066_c.pdf","us_notice_code":"公告及通告 - [中期业绩 / 修订宪章文件 / 更换董事或重要行政职能或职责的变更]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2025-08-31 18:30","pubTimestamp":1756636200,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19944295","market":"hk","labels":[],"media":"港交所","original_id":"N.HKBjBpozdtEZ","pdf_url":"https://static.tigerbbs.com/34fc3516e01d405f8935b05e06943126","pub_time":1754318520000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"完成根据一般授权配售新H股","symbol":"02410","title":"完成根据一般授权配售新H股","titleType":"股份发行","type":"hkShares","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0804/2025080402347_c.pdf","us_notice_code":"公告及通告 - [配售 / 根据一般性授权发行股份]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"股权股本","type_name_en":"Equity Change","titleTypeEn":"Share Issuance","event_type":"important_notice","event_name":"股份发行","pubTime":"2025-08-04 22:42","pubTimestamp":1754318520,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19918222","market":"hk","labels":[],"media":"港交所","original_id":"N.HK5XNhTGVFfY","pdf_url":"https://static.tigerbbs.com/ca188062973d42f3b71aee148112a82b","pub_time":1753740420000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"根据一般授权配售新H股","symbol":"02410","title":"根据一般授权配售新H股","titleType":"股份发行","type":"hkShares","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0729/2025072900004_c.pdf","us_notice_code":"公告及通告 - [配售 / 根据一般性授权发行股份]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"股权股本","type_name_en":"Equity Change","titleTypeEn":"Share Issuance","event_type":"important_notice","event_name":"股份发行","pubTime":"2025-07-29 06:07","pubTimestamp":1753740420,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19562509","market":"hk","labels":[],"media":"港交所","original_id":"N.HK6jhALatDTA","pdf_url":"https://static.tigerbbs.com/3655ef960b914b0888916cb27a57c97b","pub_time":1745916120000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2024年度报告","symbol":"02410","title":"2024年度报告","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0429/2025042901084_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [年报 / 环境、社会及管治资料/报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2025-04-29 16:42","pubTimestamp":1745916120,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19298545","market":"hk","labels":[],"media":"港交所","original_id":"N.HK5kKrBbdctD","pdf_url":"https://static.tigerbbs.com/718c98826c324bf0b2e29802f28dd06c","pub_time":1743083400000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2024年12月31日止年度年度业绩公告；非执行董事辞任；及建议修订组织章程细则","symbol":"02410","title":"截至2024年12月31日止年度年度业绩公告；非执行董事辞任；及建议修订组织章程细则","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0327/2025032702334_c.pdf","us_notice_code":"公告及通告 - [末期业绩 / 暂停办理过户登记手续或更改暂停办理过户日期 / 更换董事或重要行政职能或职责的变更 / 修...更多]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2025-03-27 21:50","pubTimestamp":1743083400,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18653724","market":"hk","labels":[],"media":"港交所","original_id":"N.HKDa8ffoZeXZ","pdf_url":"https://static.tigerbbs.com/3bf20bbd552f4fde9768a429aa07ab21","pub_time":1727426700000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2024中期报告","symbol":"02410","title":"2024中期报告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0927/2024092700920_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [中期/半年度报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2024-09-27 16:45","pubTimestamp":1727426700,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18559041","market":"hk","labels":[],"media":"港交所","original_id":"N.HKJ6zpjRgpMT","pdf_url":"https://static.tigerbbs.com/be1fa360987748aa9d1e9642550fe2d3","pub_time":1725007620000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2024年6月30日止六个月中期业绩公告","symbol":"02410","title":"截至2024年6月30日止六个月中期业绩公告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0830/2024083000942_c.pdf","us_notice_code":"公告及通告 - [中期业绩]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2024-08-30 16:47","pubTimestamp":1725007620,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18458575","market":"hk","labels":[],"media":"港交所","original_id":"N.HK8CzhcJraXG","pdf_url":"https://static.tigerbbs.com/52b2dfd43b1b4917960f378086db6cae","pub_time":1723414560000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"全球发售","symbol":"02410","title":"全球发售","titleType":"股份发售","type":"hkIPO","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0812/2024081200006_c.pdf","us_notice_code":"上市文件 - [发售以供认购]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"上市文件","type_name_en":"Listing Document","titleTypeEn":"Shares Subscription","event_type":"important_notice","event_name":"股份发售","pubTime":"2024-08-12 06:16","pubTimestamp":1723414560,"notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":true},"companyData":{"profile":{"stockEarnings":[{"period":"1week","weight":0.0226},{"period":"1month","weight":-0.0231},{"period":"3month","weight":-0.2705},{"period":"6month","weight":-0.3772},{"period":"1year","weight":-0.722},{"period":"ytd","weight":-0.722}],"compareEarnings":[{"period":"1week","weight":-0.0073},{"period":"1month","weight":-0.0155},{"period":"3month","weight":-0.0607},{"period":"6month","weight":0.0717},{"period":"1year","weight":0.2777},{"period":"ytd","weight":0.2777}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。该公司专注于小分子药物开发，其主要产品包括TY-9591、TY-302和TY-2136。TY-9591是一种第三代EGFR-TKI，对EGFR突变具有抗肿瘤作用。TY-302是一种为治疗乳腺癌及前列腺癌等晚期实体瘤而开发的强效、选择性口服CDK4/6抑制剂。TY-2136b为自主研发、口服ROS1/NTRK抑制剂，用于治疗实体瘤。","exchange":"SEHK","name":"同源康医药-B","nameEN":"TYK MEDICINES-B"},"aProfile":null}}}